Dual targeting of the mitochondrial pathway or glycolytic pathway enhances AK2-depleted phenotype in T-ALL cells. (A) Survival curves at day 3 of the CEM, JURKAT, MOLT4, and RPMI 8402 cell lines transfected with either shScramble (blue) or shAK2 (red), treated with dimethyl sulfoxide (DMSO) or increasing concentrations of venetoclax (ABT-199). Viability is shown as the percentage of Annexin V and propidium iodide (AnnV-PI)–negative cells for each condition. (B) Survival rate for each of the 4 transduced cell lines treated with either DMSO or venetoclax 5 µM at day 3 (same experiment as panel A). (C) Mean survival rate of the 4 transduced cell lines treated with either DMSO or venetoclax 5 µM at day 3 (same experiment as in panel A). (D) Survival rate at day 3 of the CEM, JURKAT, MOLT4, and RPMI 8402 cell lines transfected with either shScramble (blue) or shAK2 (red), treated with DMSO or 2.5 mM of 2-DG; viability is shown as the percentage of AnnV-PI–negative cells for each condition. All experiments were performed in technical duplicates. *P < .05; **P < .01; ***P < .001. ns, not significant.